Liver Function Tests Explained: ALT, AST, ALP, Bilirubin and How to Read the Pattern

What liver function tests actually measure

A standard liver panel — often abbreviated LFTs, for liver function tests — is a small cluster of blood measurements that together describe the state of one of the body's most metabolically active organs. Despite the name, most of the numbers on the panel are not measures of function at all. They are markers of injury and flow. The two transaminases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are enzymes that live inside liver cells; when those cells are damaged, the enzymes spill into the blood, so a rise signals hepatocyte injury rather than lost function. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) track the bile-drainage side of the system. Bilirubin measures the liver's ability to process the waste product of old red blood cells. Only two components — albumin and the prothrombin time / INR — genuinely measure synthetic function, because the liver manufactures both albumin and most clotting factors.

That distinction matters more than it sounds. A person can have strikingly abnormal enzyme numbers and a perfectly functioning liver, and — more dangerously — a person with advanced cirrhosis can have near-normal enzymes because there are few healthy cells left to leak them. This is why clinicians read the panel as a story rather than a scoreboard, and why the single most common mistake patients make is fixating on one high value in isolation. The American College of Gastroenterology (ACG), in its 2017 guidance on the evaluation of abnormal liver chemistries, explicitly frames interpretation around patterns and degree of elevation, not individual thresholds.

A comprehensive metabolic panel (CMP) drawn at most routine physicals already contains ALT, AST, ALP, total bilirubin, albumin and total protein. GGT is usually an add-on, ordered when ALP is high and the clinician needs to know whether the source is liver or bone. You can review each marker individually in our biomarker library, but the value of the panel is in how the components move together.

How the liver works and why enzymes leak

The liver sits in the upper right of the abdomen and weighs roughly 1.5 kilograms in an adult. It receives about 75 percent of its blood supply from the portal vein, which drains the entire gut, meaning almost everything you absorb — nutrients, drugs, alcohol, bacterial products — passes through the liver first. This first-pass position is why the organ is both a chemical processing plant and a frequent casualty. Hepatocytes, the workhorse cells that make up most of the liver's mass, handle protein synthesis, glucose storage, cholesterol and bile production, and the detoxification of hundreds of compounds through enzyme systems such as cytochrome P450.

ALT and AST are enzymes that catalyze the transfer of amino groups, a routine step in amino-acid metabolism. ALT lives almost entirely in the cytoplasm of hepatocytes and is highly liver-specific — which is why it is the single most useful screening enzyme. AST is less specific: it exists in liver cells, but also in heart muscle, skeletal muscle, kidney, brain and red blood cells, and it lives in two compartments, the cytoplasm and the mitochondria. When a hepatocyte membrane is injured — by fat accumulation, a virus, a toxin, or lack of oxygen — its contents leak. Mild membrane stress releases mostly cytoplasmic ALT. Severe injury that ruptures mitochondria releases the mitochondrial fraction of AST as well, which is part of why very high AST relative to ALT signals deeper cellular destruction, as seen in alcoholic hepatitis and ischemic injury.

The biliary system is a separate story. Bile — made by hepatocytes and rich in bile acids, cholesterol and bilirubin — drains through a branching tree of ducts into the common bile duct and on to the intestine. ALP and GGT are enzymes anchored to the membranes of the cells lining those ducts (the cholangiocytes). When bile flow is obstructed or the ducts are inflamed, back-pressure and bile-acid buildup trigger increased production and release of ALP and GGT. That is why a cholestatic pattern — blocked drainage, as from a gallstone in the common bile duct or a tumor at the head of the pancreas — pushes ALP and GGT up far more than the transaminases.

Bilirubin ties the two systems together. It is the yellow-orange breakdown product of heme, released when old red blood cells are recycled. The liver conjugates bilirubin (attaches sugar molecules to make it water-soluble) and excretes it in bile. Bilirubin can therefore rise for three broad reasons: too much is being produced (hemolysis, where red cells break down faster than normal), the liver cannot conjugate it efficiently (Gilbert syndrome, hepatitis), or conjugated bilirubin cannot drain out (biliary obstruction). Splitting total bilirubin into its direct (conjugated) and indirect (unconjugated) fractions is what tells these apart.

The markers one by one

ALT (alanine aminotransferase)

ALT, historically called SGPT, is the most liver-specific enzyme on the panel and the best single screening test for hepatocellular injury. Because it is concentrated in the liver, a rise almost always points there. The commonest cause of a mildly elevated ALT in a well adult worldwide is now metabolic-associated fatty liver — a topic we return to below. ALT also rises with viral hepatitis, alcohol, and a long list of drugs and supplements. Notably, research over the last two decades — including large analyses tied to the U.S. National Health and Nutrition Examination Survey (NHANES) — suggests the traditional upper limits for ALT were set too high because the reference populations quietly included people with undiagnosed fatty liver. Several expert groups now argue the true healthy ceiling is closer to 30 U/L for men and 19 to 25 U/L for women, lower than many lab report ranges. You can see the specifics for this marker on our ALT biomarker page.

AST (aspartate aminotransferase)

AST, historically SGOT, is the less specific twin. Because it is abundant in heart and skeletal muscle, an isolated high AST with a normal ALT should prompt a check for a muscle or cardiac source — after strenuous exercise, a fall, a seizure, rhabdomyolysis, or a heart attack, AST can climb without any liver disease at all. Creatine kinase (CK) is the usual tie-breaker: a high CK alongside high AST points to muscle. Within liver disease, AST becomes especially informative in relation to ALT, which is the basis of the De Ritis ratio discussed later. Detailed reference values are on our AST biomarker page.

ALP (alkaline phosphatase)

ALP is a family of enzymes found in the liver's bile ducts but also in bone, intestine, kidney and placenta. Its dual liver-and-bone origin is the crucial nuance. A high ALP in a growing teenager is usually normal bone growth. A high ALP in a pregnant woman is usually the placenta. A high ALP in an older adult may be Paget's disease of bone, a vitamin D problem, or bile-duct obstruction. This is exactly why GGT exists as a companion test: GGT rises with biliary disease but not with bone disease, so a high ALP with a high GGT means the liver, whereas a high ALP with a normal GGT points away from the liver and toward bone. Our alkaline phosphatase page lists the age- and sex-specific ranges.

GGT (gamma-glutamyl transferase)

GGT is a sensitive but non-specific marker of biliary and hepatocyte membrane stress. Its main clinical jobs are twofold: confirming that a high ALP is coming from the liver rather than bone, and flagging alcohol use, because chronic drinking induces the enzyme. GGT is also raised by many enzyme-inducing drugs and by fatty liver. Because it is so easily nudged, an isolated high GGT with everything else normal is common and usually not alarming on its own — its power is as a corroborating signal, not a stand-alone alarm. GGT does not currently have a dedicated page in our biomarker library, but it is always interpreted alongside ALP.

Bilirubin (total, direct and indirect)

Total bilirubin is what most panels report; splitting it into direct and indirect fractions is the key follow-up when it is high. A predominantly indirect (unconjugated) rise with normal enzymes usually means either mild hemolysis or Gilbert syndrome, an entirely benign inherited variant present in up to 5 to 10 percent of people that causes mild jaundice under stress, fasting or illness. A predominantly direct (conjugated) rise means the liver conjugated the bilirubin but it could not drain — pointing to hepatocellular disease or biliary obstruction. Visible yellowing of the skin and eyes (jaundice) generally appears once total bilirubin passes roughly 2.5 to 3 mg/dL. See the ranges on our total bilirubin page.

Albumin and total protein

Albumin is the most abundant protein in blood, made exclusively by the liver, and one of the few true tests of synthetic function on the panel. Because albumin has a half-life of about three weeks, a low value reflects a chronic problem rather than an acute one — chronic liver disease, but also malnutrition, kidney protein loss (nephrotic syndrome), gut protein loss, and systemic inflammation, which suppresses albumin production. Low albumin in the context of otherwise abnormal LFTs raises concern for established, longer-standing liver disease.

Prothrombin time / INR

Not part of every routine panel, but the sharpest measure of the liver's synthetic capacity in an acute setting. The liver makes most clotting factors, several of them short-lived, so when it fails acutely — as in severe acetaminophen poisoning or fulminant hepatitis — the INR rises within hours to days, long before albumin would fall. A rising INR in a person with acute liver injury is a genuine red flag that belongs in an emergency department, not a re-test in six weeks.

Reference ranges and why normal varies

Reference ranges are not laws of nature. They are statistical intervals, usually built to capture the central 95 percent of a reference population, which means about 1 in 20 healthy people will fall outside the range on any given marker purely by chance. They also vary by the analyzer, the assay method, the population sampled, and — importantly for liver enzymes — by sex and age. The International Federation of Clinical Chemistry (IFCC) publishes standardized methods so results are comparable across labs, and pediatric projects such as CALIPER in Canada and the Nordic NORIP reference work exist precisely because a child's or adolescent's normal ALP is far higher than an adult's during periods of bone growth. Always read your result against the range printed on your lab's report.

Ratios and patterns that matter

The single most useful derived number on the panel is the AST/ALT ratio, known as the De Ritis ratio after the Italian physician who described it in 1957. In most forms of liver injury — fatty liver, acute viral hepatitis, most drug injury — ALT is higher than AST, so the ratio sits below 1. Two situations flip it. First, alcohol-related liver disease: chronic drinking depletes a cofactor (pyridoxal-5-phosphate, the active form of vitamin B6) that ALT needs more than AST, so ALT is suppressed and the ratio classically rises above 2, usually with a raised GGT and only moderately elevated absolute numbers. Second, advanced fibrosis or cirrhosis of any cause: as the liver scars, the ratio drifts upward and can cross 1, so a De Ritis ratio above 1 in someone with known chronic liver disease is a hint that scarring has progressed.

The second key relationship is ALP with GGT. A high ALP alone is ambiguous between liver and bone. Pairing it with GGT resolves the question: high ALP plus high GGT means the biliary system; high ALP plus normal GGT means the source is almost certainly bone (or, in a pregnant woman, the placenta). This simple two-marker logic saves a great deal of unnecessary liver imaging.

A third useful concept is the R-factor, used mainly in suspected drug-induced injury, which mathematically compares how far ALT is above its ceiling versus how far ALP is above its ceiling, to classify injury as hepatocellular, cholestatic, or mixed. You do not need to compute it yourself, but it is the formal version of the pattern-reading described in the next section.

Hepatocellular, cholestatic and mixed pictures

Clinicians sort abnormal liver panels into three broad patterns before they think about specific diseases. This triage is the backbone of the ACG and NICE approaches, and it is exactly the logic an AI analyzer applies first.

Hepatocellular pattern

Here the transaminases (ALT, AST) are the dominant abnormality, disproportionately higher than ALP. This pattern says liver cells are being damaged. The differential ranges from very common and mild — fatty liver, a few weeks of heavier drinking, a new statin — to acute and dangerous — acute viral hepatitis, autoimmune hepatitis, acetaminophen (paracetamol) toxicity, or ischemic 'shock liver' after a period of low blood pressure. The absolute height of the enzymes narrows it down: mild elevations favor fatty liver; enzymes in the thousands narrow the field sharply to acute viral hepatitis, toxin, or ischemia.

Cholestatic pattern

Here ALP and GGT dominate, with the transaminases relatively spared, and bilirubin often rising as obstruction worsens. This pattern says bile is not draining. Causes split into obstruction of the large ducts — a gallstone lodged in the common bile duct, a stricture, a tumor of the pancreatic head or bile duct — and diseases of the small ducts inside the liver, such as primary biliary cholangitis (an autoimmune condition affecting mostly middle-aged women, marked by anti-mitochondrial antibodies) and primary sclerosing cholangitis. A cholestatic picture with pain, fever and jaundice is a surgical and infectious emergency (ascending cholangitis) rather than a watch-and-wait situation.

Mixed pattern

Many real-world panels do not read cleanly. A mixed pattern — both transaminases and ALP elevated without one clearly dominating — is common in drug-induced liver injury, some viral hepatitides, and infiltrative diseases. Mixed pictures are where careful history (medications, supplements, alcohol, travel, risk factors) and follow-up testing earn their keep, and where a naive single-number reading is most likely to mislead.

Causes of high liver enzymes

Elevated liver enzymes are among the most common incidental findings in all of medicine — studies estimate that up to 1 in 10 adults has at least one abnormal liver chemistry on routine testing, and the large majority are mild and benign. The trick is knowing which causes are common-and-harmless and which are rare-but-serious. The list below runs roughly from most to least common in the general adult population.

• Metabolic-associated fatty liver disease (MASLD, formerly NAFLD) — by far the leading cause of mildly elevated ALT worldwide, driven by excess weight, insulin resistance, high triglycerides and type 2 diabetes. Renamed by the AASLD and EASL in 2023 to reflect its metabolic roots.
• Alcohol — even a few weeks of heavier drinking raises GGT and can raise AST; the classic De Ritis ratio above 2 with high GGT is the fingerprint.
• Medications and supplements — statins, certain antibiotics (amoxicillin-clavulanate is a leading cause of drug-induced cholestasis), anti-tuberculosis drugs, methotrexate, high-dose acetaminophen, anabolic steroids, high-dose niacin, kava, green-tea extract and some bodybuilding supplements.
• Viral hepatitis — hepatitis B and C (often chronic and silent for years), hepatitis A and E (usually acute and self-limited). The WHO estimates hundreds of millions of people live with chronic hepatitis B or C, most undiagnosed.
• Autoimmune and genetic liver disease — autoimmune hepatitis, hemochromatosis (iron overload), Wilson's disease (copper overload), alpha-1 antitrypsin deficiency.
• Biliary obstruction — gallstones, strictures, and tumors producing a cholestatic pattern.
• Non-liver sources — vigorous exercise, muscle injury, thyroid disease, celiac disease and heart failure can all nudge liver chemistries, which is why AST in particular must be interpreted with muscle and cardiac sources in mind.

Because MASLD sits at the intersection of the liver, the pancreas and the arteries, an abnormal ALT rarely travels alone. It commonly appears alongside a high triglyceride, a low HDL and a rising HbA1c — which is why our HbA1c guide and lipid panel guide are natural companion reading for anyone with an unexplained enzyme rise. Iron studies, including ferritin, are also part of the standard work-up, both to screen for hemochromatosis and because ferritin rises in inflamed fatty liver.

Low values and what they mean

Low liver enzymes are usually reassuring or clinically silent, but not always meaningless. A low ALT or AST on its own is generally of no concern, though a persistently very low ALT has been associated in some studies with frailty, sarcopenia (low muscle mass) and vitamin B6 deficiency in older adults, because the enzyme's activity depends on that vitamin. Low ALP is the more informative low value: it can point to zinc or magnesium deficiency, malnutrition, hypothyroidism, and — rarely but importantly — Wilson's disease and the inherited condition hypophosphatasia. Low albumin, discussed above, is never dismissed lightly; it reflects chronic illness, inflammation, poor nutrition, or protein loss, and it is one of the components that helps stage established liver disease.

How high is dangerous? Thresholds that change urgency

Patients understandably want a single cut-off between safe and dangerous, but the honest answer is that how high matters far more than whether a value is above the range, and it interacts with symptoms. Clinicians think in multiples of the upper limit of normal (ULN). The following rough bands, aligned with ACG and NICE guidance, describe how the degree of transaminase elevation shifts the differential and the urgency — but they are educational, not a substitute for a clinician's judgment about your specific situation.

Who is most at risk

Some people carry a higher pre-test probability of abnormal liver chemistries and benefit from a lower threshold for testing and follow-up. The strongest risk factors cluster around metabolic health, alcohol, and specific exposures.

• Metabolic risk — overweight or obesity, type 2 diabetes or prediabetes, high triglycerides, low HDL, and high blood pressure. This cluster (metabolic syndrome) is the engine of MASLD.
• Alcohol use — the risk rises with quantity and duration; the WHO is explicit that no level of alcohol is entirely without risk to the liver.
• Viral exposure — the CDC recommends one-time hepatitis C screening for all adults, and hepatitis B screening for those at risk; risk factors include past injection drug use, blood transfusion before the early 1990s, and birth in a region with high endemic rates.
• Polypharmacy and supplement use — people taking multiple medications, herbal remedies or bodybuilding supplements.
• Family history — of hemochromatosis, Wilson's disease, or early liver disease.
• Older adults and those with sarcopenia — for whom low as well as high values carry meaning.

How the test is done and how to prepare

A liver panel is a standard venous blood draw, usually from the arm, and the enzymes are measured by automated analyzers using standardized IFCC methods. The sample is typically serum. For most components no special preparation is required, but a few practical points improve the reliability of the result.

• Fasting is not strictly required for LFTs, but because they are frequently drawn together with glucose and a lipid panel, you may be asked to fast 8–12 hours; a heavy fatty meal can transiently affect some results.
• Avoid vigorous exercise for a day or two before the draw — heavy exertion can raise AST (and CK) from muscle and be mistaken for liver injury.
• Alcohol in the days before testing raises GGT and can raise AST; if the goal is a clean baseline, a short abstinence gives a truer picture.
• List every medication and supplement, including over-the-counter painkillers, herbal products and protein or bodybuilding supplements, so results can be interpreted against real exposures.
• Hemolysis of the sample — red cells breaking during a difficult draw — can falsely raise AST and bilirubin, occasionally prompting a repeat test.

Results are usually available within a day. Because reference ranges and units differ between laboratories (U/L for enzymes, and mg/dL versus µmol/L for bilirubin in different countries), always compare your value with the range printed on your own report rather than a figure from the internet.

Related conditions LFTs help detect

MASLD / MASH (fatty liver disease)

Metabolic-associated steatotic liver disease is now the most common chronic liver condition on earth, affecting an estimated quarter to a third of adults in many countries. Most people have simple fat accumulation with mildly elevated ALT and no symptoms. In a minority, the fat is accompanied by inflammation and cell injury — metabolic-associated steatohepatitis, MASH — which over years can progress to fibrosis and cirrhosis. Because enzyme levels correlate poorly with how much scarring is present, guidelines from the AASLD and NICE increasingly recommend combining blood markers into fibrosis scores (such as the FIB-4 index, which uses age, AST, ALT and platelet count) and, where indicated, elastography imaging to estimate scarring. The good news is that MASLD is highly responsive to weight loss and metabolic control.

Viral hepatitis

Hepatitis B and C are the classic silent causes of chronic enzyme elevation, often symptomless for decades while quietly driving fibrosis and raising the long-term risk of cirrhosis and liver cancer. The WHO has set a global target to eliminate viral hepatitis as a public health threat by 2030, and modern direct-acting antivirals now cure the great majority of hepatitis C cases. This is why an unexplained persistent ALT elevation routinely triggers hepatitis serology — the condition is treatable, and finding it early changes the trajectory.

Alcohol-related liver disease and cirrhosis

Alcohol-related injury spans a spectrum from reversible fatty change to alcoholic hepatitis to cirrhosis. The enzyme signature — modest absolute elevations with an AST/ALT ratio above 2 and a raised GGT — is characteristic, but as scarring advances the enzymes can normalize even as function declines, which is why albumin, bilirubin and INR become the more telling numbers in established disease.

Inherited and autoimmune disease

Hemochromatosis (iron overload), Wilson's disease (copper overload), alpha-1 antitrypsin deficiency, autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis are individually uncommon but collectively important because they are treatable and because they strike people without the usual metabolic or alcohol risk factors. A persistent abnormality in a young, lean, non-drinking person specifically raises the priority of hunting for these.

How AI reads your liver panel in context

An AI lab analyzer — such as the Kantesti AI engine that powers the blood-test.life analyzer — is well suited to liver panels precisely because the interpretation is fundamentally about relationships between numbers, not single thresholds. Where a person scanning a report tends to fixate on the one value flagged in red, a well-designed model evaluates the whole vector at once and reconstructs the clinical logic described throughout this guide.

• Pattern classification first — it compares the transaminases against ALP and GGT to decide whether the picture is hepatocellular, cholestatic or mixed, rather than reacting to any one high value.
• Ratio computation — it calculates the AST/ALT (De Ritis) ratio and checks it against GGT to distinguish, for example, alcohol-related change from fatty liver.
• Cross-panel correlation — it reads the liver numbers alongside glucose, HbA1c, triglycerides, HDL and platelets, because a mild ALT rise with a high HbA1c and low HDL tells a metabolic story that ALT alone cannot.
• Fraction and trend awareness — where direct and indirect bilirubin or prior results are available, it can separate a benign Gilbert pattern from something requiring follow-up, and weigh a rising trend more heavily than a single snapshot.
• Plain-language explanation — it translates all of this into readable context with clear pointers on when to see a clinician.

None of this replaces a physician. An AI analyzer is an educational and triage aid that helps you arrive at an appointment better informed and ask sharper questions — it does not examine you, order confirmatory tests, or prescribe. You can read more about the method and its limits on our how it works page, and see coverage and options on the pricing page.

When to see a clinician

Most mildly abnormal liver panels are handled calmly in primary care with a history, a few extra blood tests, and a repeat in a few weeks. But some situations warrant faster action, and a handful warrant same-day emergency care.

See a clinician soon (days to weeks)

• Any liver enzyme persistently above the reference range on a repeat test.
• An ALT or AST more than about 3 times the upper limit, even without symptoms.
• A new cholestatic pattern (high ALP with high GGT), which needs imaging of the bile ducts.
• Abnormal liver chemistries with risk factors: heavy alcohol use, hepatitis exposure, diabetes, obesity, or a family history of liver disease.
• Low albumin or an unexplained abnormal result in a young, lean, non-drinking person.

Seek same-day or emergency care

• New jaundice — yellowing of the eyes or skin.
• Right-upper-abdominal pain with fever (possible ascending cholangitis).
• Confusion, marked drowsiness, or personality change (possible hepatic encephalopathy).
• Easy bruising, bleeding, or a known rising INR.
• Any known or suspected acetaminophen (paracetamol) overdose — antidote treatment is time-critical and highly effective when given early.

Lifestyle and next steps to lower enzymes

Because the most common cause of mildly elevated enzymes is metabolic fatty liver, the most effective interventions are the ones that improve metabolic health — and they work. Multiple studies and guideline statements from the AASLD converge on a striking figure: losing around 7 to 10 percent of body weight can substantially reduce liver fat, calm inflammation, and in many people improve or resolve fibrosis. The steps below are general health information, not a personalized treatment plan; anyone with persistently abnormal results should act on them under a clinician's guidance.

1. Gradual, sustained weight loss if overweight — targeting 7–10 percent of body weight, which is more impactful for the liver than any supplement.
2. Reduce or stop alcohol — the single fastest way to bring down a GGT-driven, alcohol-related elevation; even a few weeks of abstinence can visibly improve numbers.
3. Cut added sugar and refined carbohydrate, especially fructose-heavy drinks — dietary sugar is a direct driver of liver fat.
4. Adopt a Mediterranean-style eating pattern — rich in vegetables, legumes, whole grains, fish and olive oil, repeatedly linked to lower liver fat.
5. Move regularly — both aerobic exercise and resistance training reduce liver fat independent of weight loss; aim for the widely recommended 150 minutes of moderate activity per week.
6. Review medications and supplements with a pharmacist or doctor — stop non-essential agents that stress the liver, and never exceed acetaminophen dosing limits.
7. Control diabetes, blood pressure and cholesterol — treating the metabolic drivers treats the liver.
8. Vaccinate against hepatitis A and B if not already immune, and get tested for hepatitis C once as the CDC advises.
9. Re-test as advised — usually in 4 to 12 weeks — so your clinician can read the trend, which is far more informative than a single value.

Myths and misconceptions

Myth: normal liver enzymes mean a healthy liver

False, and dangerously so. People with cirrhosis frequently have normal or only mildly elevated enzymes, because scarred livers have few cells left to leak them. Enzymes measure ongoing injury, not the total amount of accumulated damage or remaining function. This is why fibrosis scores, imaging and the synthetic markers (albumin, INR) exist.

Myth: a high enzyme always means liver damage

Not necessarily. A high AST can come from muscle after a hard workout, a fall, or a heart problem. A high ALP can come from bone or pregnancy. A mildly high bilirubin is often benign Gilbert syndrome. Context and companion markers (CK for muscle, GGT for the ALP source, bilirubin fractions) sort these out.

Myth: liver detox teas, milk thistle or cleanses fix elevated enzymes

There is no robust evidence that commercial detox products lower liver enzymes or reverse liver disease, and — paradoxically — some herbal and 'detox' supplements are themselves causes of drug-induced liver injury. Green-tea extract and kava are documented offenders. The genuinely effective interventions are unglamorous: weight loss, less alcohol, better diet, exercise, and treating the underlying cause.

Myth: you would feel it if your liver were in trouble

The liver is famously silent. Chronic hepatitis and fatty liver commonly progress for years or decades without symptoms, which is precisely why blood testing matters — it detects a problem while it is still reversible, long before pain, jaundice or swelling would ever appear.

Limitations: what LFTs cannot tell you

Liver function tests are a powerful, cheap, widely available screen — but they are a starting point, not a diagnosis, and it is important to be honest about their limits. They cannot, by themselves, tell you how much scarring (fibrosis) a liver has, which requires fibrosis scoring, elastography or occasionally biopsy. They cannot distinguish the many possible causes of an abnormality without history and follow-up testing. They can be normal in serious disease and abnormal in trivial circumstances. And a single result is far less informative than a trend.

blood-test.life and its AI analyzer are educational tools designed to help you understand your results and know what to ask — they are not a medical device, not a diagnosis, and not a substitute for professional care. If you have symptoms — jaundice, abdominal pain, confusion, bleeding — or a result that concerns you, contact a qualified clinician promptly. The purpose of understanding your liver panel is not to self-treat, but to have a more informed, more useful conversation with the person who can.

Frequently asked questions